Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential

Executive Summary

After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.

You may also be interested in...



FDA Migraine Guidance Offers ‘Alternative’ Trial Design With Patient-Focused Endpoint

Sponsor would need “no pain” result at two hours, but could use patient-identified symptom as co-primary endpoint.

FDA Migraine Guidance Offers ‘Alternative’ Trial Design With Patient-Focused Endpoint

Sponsor would need ‘no pain’ result at two hours, but could use patient-identified symptom as co-primary endpoint.

Allergan Hopes To Shed Excess Fat As It Grows Other Franchises

The Irvine, Calif.-based company reported full-year results on Feb. 5 that highlighted the growth of its Botox business to several new indications.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS054465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel